Abstract:ObjectivesTo explore the expression level, association with disease activity and clinical significance of hsa_circ_0008301 in the peripheral blood of patients with primary Sjögren's syndrome (pSS).MethodsWe selected 70 pSS patients hospitalized under the Rheumatology service line at the General Hospital of Ningxia Medical University from September 2018 to June 2021 as the disease group, in which general data and clinical indicators were collected. Fifty-three patients with healthy physical examinations for the same period were selected as the healthy control group, and 32 patients with non-pSS rheumatic diseases were selected as the disease control group. We collected peripheral blood samples and used fluorescence quantitative PCR to detect the expression level of hsa_circ_0008301. In addition, we analyzed the association of the expression level of hsa_circ_0008301 with the clinical characteristics and disease activity of pSS patients. A receiver operating characteristic curve was used to evaluate the diagnosis and the disease activity value of hsa_circ_0008301 in patients with pSS. Meanwhile, we analyzed the differential expression of hsa_circ_0008301 in 24 pSS patients selected from the disease group before and after treatment.ResultsThe relative expression of hsa_circ_0008301 in the peripheral blood of pSS patients was significantly higher than that in the control groups including healthy control group and disease control group. The expression level of hsa_circ_0008301 was high in pSS patients with a course of disease ≥ 10 years, fatigue symptoms, platelets 16 g/L, complement C3 < 0.9 g/L, ESSDAI score ≥ 5 and positively correlated with the above groups. Furthermore, ROC analysis showed that hsa_circ_0008301 was statistically significant between pSS patients and healthy controls. We selected patients from the disease group before and after treatment and showed that the expression level of hsa_circ_0008301 decreased significantly after treatment, compared with before. The area under the curve (AUC) was 0.825 (95% CI: 0.754 ∼ 0.897; P 0.0420, and the maximum Youden index was 0.337. In addition, ROC analysis revealed that hsa_circ_0008301 was statistically significant between disease-active patients and stable patients. The AUC value was 0.681 (95% CI: 0.553 ∼ 0.809; P = 0.010), the sensitivity was 65.90%, the specificity was 72.40%, the optimal truncation value was > 0.0285, and the maximum Youden index was 0.383. ROC analysis indicated that hsa_circ_0008301 has some value in the diagnosis and disease activity of patients with pSS. Comparison of 24 pSS patients selected from the disease group before and after treatment showed that the expression level of hsa_circ_0008301 decreased significantly after treatment compared with before treatment (Z = − 4.257, P < 0.0001). ROC analysis indicated that hsa_circ_0008301 has some value in the diagnosis and disease activity of patients with pSS.ConclusionsHsa_circ_0008301 is expressed in higher levels in the peripheral blood of patients with pSS, which is related to the disease activity. It may be involved in the occurrence and development of pSS and may have a potential biomarker for the disease.

A study on factors related to sleep disorders and serum BDNF expression levels in patients with primary Sjӧgren's syndrome

[Investigation of sleep disturbance and related factors in patients with primary Sjögren's syndrome]

Biomarkers for Primary Sjögren’s Syndrome

[Probe into Sleep Quality in the Patients with Irritable Bowel Syndrome].

Effect of Chinese Herbal Medicines for Nourishing Yin, Supplementing Qi, and Activating Blood on Reproductive Endocrine Activity and Immune Functions in Patients with Primary Sjogren's Syndrome.

The frequency of obstructive sleep apnea in patients with primary Sjogren's syndrome

Serum levels of neurotensin, pannexin-1, and sestrin-2 and the correlations with sleep quality or/and cognitive function in the patients with chronic insomnia disorder

Associations of Sleep Disorders with Cerebrospinal Fluid Α-Synuclein in Prodromal and Early Parkinson’s Disease

Psychological factors and biochemical indicators influencing sleep disturbance of patients with primary biliary cholangitis in China: a cross-sectional survey analysis

Evaluation of Diagnostic Efficiency of Clinical Indicators in Patients with Primary Sjogren′s Syndrome

Expression of FcγRⅡb on peripheral B cells and its clinical significance in patients with primary Sj(o)gren's syndrome

Associated Factors with Interstitial Lung Disease and Health-Related Quality of Life in Chinese Patients with Primary Sjögren’s Syndrome

Hsa_circ_0008301 as a potential biomarker of disease activity for primary Sjogren's syndrome: Increased expression in peripheral blood of patients with primary Sjogren's syndrome

Prevalence, severity, and predictors of dry eye and dry mouth in Chinese patients with primary Sjögren syndrome

Clinical Significance of the Expression Levels of Serum Transforming Growth Factor-Β and CXC Type Chemokine Ligand 13 in Primary Sjogren's Syndrome Patients.

Sleep Disorders in Chinese Patients with Parkinson's Disease: Validation Study of a Chinese Version of Parkinson's Disease Sleep Scale

Clinical analysis of the neurological involvement in primary Sj(o)gren's syndrome

Associations between sleep disorders and clinical outcomes of patients with primary biliary cholangitis

Survey of Factors Influencingsleep Disorder Inpatients with A myotrophic Lateral Sclerosis

The Relationship between Sleep Parameters Measured by Polysomnography and Selected Neurotrophic Factors

Sleep quality and clinical association with sleep disturbance in systemic sclerosis